Explore

Stratified Medicine Advances in Oncology with Focus on Rare Cancers and Drug Repurposing

Stratified Medicine Advances in Oncology with Focus on Rare Cancers and Drug Repurposing

Stratified medicine, also known as precision medicine, is evolving to tailor disease prevention, diagnosis, and treatment based on an individual's genetic, protein, environmental, and lifestyle information. In oncology, a tumor budding-based grading system, proposed by the International Association for the Study of Lung Cancer (IASLC), is being utilized to stratify risk in patients with resected lung squamous cell carcinoma (SqCC). This system helps identify individuals who may benefit from adjuvant chemotherapy. Furthermore, recent advancements in precision oncology are enabling tumor-agnostic repurposing methods. These methods are crucial for identifying new therapeutic opportunities, particularly for rare and ultra-rare cancers, where traditional treatment options are often limited or non-existent. The approach involves leveraging existing genomic data from routine clinical care to find new uses for established drugs, moving beyond conventional 'on-target' approaches to explore 'off-target' vulnerabilit...

Morgan Stanley Conference Highlights Untapped GLP-1 Potential and AI's Role in Healthcare

Morgan Stanley Conference Highlights Untapped GLP-1 Potential and AI's Role in Healthcare

Morgan Stanley Conference Highlights Untapped GLP-1 Potential and AI's Role in Healthcare

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified medicine, also known as precision medicine, is evolving rapidly through the integration of artificial intelligence (AI) and genomic technologies. This approach focuses on customizing medical treatment for individual patients by utilizing biomarkers to identify specific subgroups within a diagnosis. The advancements allow for more targeted and effective therapies. AI and genomic technologies are enhancing the analysis of complex multimodal data, which includes imaging, physiological signals, and electronic health records. This comprehensive data analysis supports earlier diagnosis, more refined phenotyping, and improved risk stratification across various medical conditions. High-throughput pluripotent stem cell models combined with AI modeling are accelerating the development of precision medicine, particularly in fields such as oncology, neurodevelopmental and neurodegenerative disorders, and metabolic diseases. This shift moves away from a one-size-fits-all medical approach towards treatments t...

ARK Invest Adjusts Portfolio, Trims Tempus AI Holdings Amid Broader Market Shifts

ARK Invest Adjusts Portfolio, Trims Tempus AI Holdings Amid Broader Market Shifts

ARK Invest Adjusts Portfolio, Trims Tempus AI Holdings Amid Broader Market Shifts

Tumors Can Evade T-Cell Recognition by Hiding p53 Neoantigens, Study Reveals

Tumors Can Evade T-Cell Recognition by Hiding p53 Neoantigens, Study Reveals

New research from Dana-Farber Cancer Institute and Harvard Medical School indicates that tumors can actively conceal p53-derived neoantigens from T cells, allowing cancer cells to evade immune system detection. The study, published in Immunity, found that while mutations in the TP53 gene are common in cancer and represent attractive targets for immunotherapy, the presence of a mutation does not guarantee its visibility to T cells. T cells recognize short peptides presented by human leukocyte antigen (HLA) molecules. The researchers discovered that mechanisms exist within tumors that restrict the presentation of these p53 peptides on the cell surface. For instance, the enzyme ERAP1 can destroy the neoantigen before it reaches the cell surface, as observed with the p53 I195F mutation. Another common mutation, p53 R175H, showed weak binding to HLA-A*02:01, resulting in an unstable complex and reduced T-cell activation. These findings suggest that genomic sequencing and computational predictions alone may over...

University of Texas MD Anderson Cancer Center Identifies B Cells as Key in Immunotherapy-Related Colitis

University of Texas MD Anderson Cancer Center Identifies B Cells as Key in Immunotherapy-Related Colitis

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a significant role for B cells in the development and persistence of colitis, a severe side effect of immune checkpoint inhibitors used in cancer treatment. The study, published in Cell Reports, was led by Roza Nurieva, Ph.D., professor of Immunology. The findings indicate that changes in circulating B cell activity can occur before patients experience any symptoms, suggesting B cells could serve as a predictive biomarker for the risk of immunotherapy-related colitis. Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing the immune system's ability to fight cancer, but they can also trigger severe immune-related adverse events, including colitis, which causes inflammation of the colon, severe diarrhea, abdominal pain, and intestinal bleeding. The study found that higher levels of B cells before treatment were associated with an increased risk of colitis, and preclinical models showed that B cell activat...

Boston University Researchers Develop Scalable Method for CAR-T Cancer Treatment

Boston University Researchers Develop Scalable Method for CAR-T Cancer Treatment

Researchers at the Center for Regenerative Medicine at Boston Medical Center and Boston University have developed a new, scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs). This breakthrough, published in Stem Cell Reports, addresses a significant challenge in the development of 'off-the-shelf' CAR-T therapies. Current CAR-T treatments involve collecting a patient's T cells, genetically modifying them to target cancer, and then reintroducing them, a process that is both expensive and time-consuming. The Boston team, led by Dr. Gustavo Mostoslavsky and doctoral student Julian Amirault, focused on manipulating the Notch molecular signaling pathway. They found that by removing Notch signaling during later stages of T cell maturation and simultaneously reducing anti-T cell receptor signaling, they could enable developing cells to survive and mature into functional CD4+ T cells at scale. This protocol is described as simple, straightforward, and potentially scalable f...

CRISPR Activation Tool Identifies Genes Linked to Lymphoma Drug Resistance and Tumor Growth

CRISPR Activation Tool Identifies Genes Linked to Lymphoma Drug Resistance and Tumor Growth

Researchers have utilized a novel whole-genome CRISPR screening platform, named Partita, to identify genes associated with drug resistance in lymphoma cells and those that accelerate tumor growth. This new CRISPR activation technology, unlike traditional CRISPR methods that disrupt genes, allows for the activation of every gene in the mouse genome, one at a time, in both cellular and live models. The study, published in Science Advances, revealed that activating the Irx5 gene in cancer cells led to resistance against venetoclax, a commonly used blood cancer drug, by increasing a protein involved in cell survival. In live mice, Partita helped identify three genes—Runx2, Runx3, and Csf1r—that accelerate the growth of MYC-driven lymphoma, a type of cancer that is currently challenging to treat. This research provides new insights into the mechanisms of cancer progression and drug resistance, offering potential targets for future therapeutic interventions.

AI System Accurately Reads Doctors' Written Notes, Unlocking Vast Medical Data for Research

AI System Accurately Reads Doctors' Written Notes, Unlocking Vast Medical Data for Research

Researchers from RespondHealth, Drexel University, Stanford University, the University of Miami, the University of Pennsylvania, and the Icahn School of Medicine at Mount Sinai have developed an AI system capable of accurately reading and analyzing doctors' handwritten clinical notes at scale. Published in Nature Medicine, this system converts narrative text into computable data, linking every extracted fact back to its original sentence. This innovation addresses a long-standing challenge in medical research, as a significant portion of patient information, including crucial details about patient coping mechanisms, side effects, and medication changes, resides in these previously inaccessible written notes. The system achieved a 99.4% accuracy rate in a combined measure of correctness and completeness when compared against an adjudicated standard set by board-certified physicians. This level of accuracy is particularly noteworthy given that physicians themselves agreed on 94.7% of statements they reviewed...

Novo Nordisk Partners with Anthropic to Integrate AI in Drug Discovery and Development

Novo Nordisk Partners with Anthropic to Integrate AI in Drug Discovery and Development

Novo Nordisk Partners with Anthropic to Integrate AI in Drug Discovery and Development

WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic

WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic

WilmerHale Advises Thermo Fisher Scientific in Biomedical Data Venture with Mayo Clinic

UCLA Health Jonsson Comprehensive Cancer Center Advances Colorectal and Prostate Cancer Research

UCLA Health Jonsson Comprehensive Cancer Center Advances Colorectal and Prostate Cancer Research

UCLA Health Jonsson Comprehensive Cancer Center has reported significant advancements in cancer research, particularly in the areas of colorectal and prostate cancer. For colorectal cancer, researchers are focusing on improving screening methods for younger adults and developing new immunotherapy and vaccine strategies. In prostate cancer, UCLA investigators are utilizing artificial intelligence to precisely map the boundaries of cancerous tissue. This AI-driven approach aims to enhance diagnostic accuracy, refine treatment planning, and improve the effectiveness of surgical procedures. These efforts are part of a broader mission at UCLA to accelerate discoveries that prevent and cure cancer, building on a legacy of transforming scientific hope into tangible progress for patients. The center has also been instrumental in the development of targeted therapies like Ibrance, which has redefined treatment for advanced ER+/HER2- breast cancer since its FDA approval in 2015.